ES2126145T3 - Redireccionamiento de anticuerpos. - Google Patents
Redireccionamiento de anticuerpos.Info
- Publication number
- ES2126145T3 ES2126145T3 ES94926336T ES94926336T ES2126145T3 ES 2126145 T3 ES2126145 T3 ES 2126145T3 ES 94926336 T ES94926336 T ES 94926336T ES 94926336 T ES94926336 T ES 94926336T ES 2126145 T3 ES2126145 T3 ES 2126145T3
- Authority
- ES
- Spain
- Prior art keywords
- linking
- antibody
- specificity
- target
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 230000004520 agglutination Effects 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
- C12N2310/1241—Tetrahymena
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
Abstract
LOS ANTICUERPOS SE REENCAMINAN A UN OBJETIVO PARA EL QUE NO TIENE UNA ESPECIFICIDAD FUNCIONAL BAJO CIRCUNSTANCIAS NORMALES. SE UTILIZA UNA SUSTANCIA DE ENLACE MULTIESPECIFICA QUE TIENE UNA ESPECIFICIDAD DE ENLACE PARA EL OBJETIVO Y UNA ESPECIFICIDAD DE ENLACE A ANTIANTICUERPOS. LA SUSTANCIA DE ENLACE PUEDE INCLUIR UNA REGION DE ENLACE DE ANTIGENOS DE LA INMUNOGLOBULINA Y PUEDE SER UN "DIACUERPO". DEPENDIENDO DEL ANTICUERPO QUE SE TRATE, SE SELECCIONAN FUNCIONES EFECTORAS TALES COMO COMPLEMENTO, ADCC Y BLOQUEO INMUNE PARA QUE ACTUEN EN EL OBJETIVO. EJEMPLOS DE OBJETIVOS SON LAS CELULAS HUMANAS. SE PRESENTAN EJEMPLOS DE UTILIZACION IN VIVO E IN VITRO, INCLUIDA LA LISIS DE CELULAS TUMORALES Y AGLUTINACION DE LOS HEMATIES DE LA SANGRE.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939319969A GB9319969D0 (en) | 1993-09-22 | 1993-09-22 | Binding proteins iv |
PCT/GB1993/002492 WO1994013804A1 (en) | 1992-12-04 | 1993-12-03 | Multivalent and multispecific binding proteins, their manufacture and use |
GB9412166A GB9412166D0 (en) | 1993-09-22 | 1994-06-17 | Retargetting antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2126145T3 true ES2126145T3 (es) | 1999-03-16 |
Family
ID=26303591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94926336T Expired - Lifetime ES2126145T3 (es) | 1993-09-22 | 1994-09-16 | Redireccionamiento de anticuerpos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US6589527B1 (es) |
EP (1) | EP0720624B1 (es) |
JP (1) | JPH09503759A (es) |
AT (1) | ATE173740T1 (es) |
AU (1) | AU680685B2 (es) |
CA (1) | CA2169620A1 (es) |
DE (1) | DE69414870T2 (es) |
DK (1) | DK0720624T3 (es) |
ES (1) | ES2126145T3 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2308982B1 (en) * | 2000-04-17 | 2014-11-26 | Dyax Corp. | Methods of constructing display libraries of genetic packages for members of a diverse family of peptides |
US8288322B2 (en) * | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
EP2316940B1 (en) | 2000-12-18 | 2013-07-24 | Dyax Corp. | Focused libraries of genetic packages |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US20050266425A1 (en) * | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
SI2298815T1 (sl) | 2005-07-25 | 2015-08-31 | Emergent Product Development Seattle, Llc | Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20 |
JP2009531324A (ja) | 2006-03-20 | 2009-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌標的化のための操作された抗前立腺幹細胞抗原(psca)抗体 |
NZ612319A (en) | 2006-06-12 | 2015-04-24 | Emergent Product Dev Seattle | Single-chain multivalent binding proteins with effector function |
JP6126773B2 (ja) | 2007-09-04 | 2017-05-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原(psca)抗体 |
AU2008298603B2 (en) * | 2007-09-14 | 2015-04-30 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
WO2009114815A1 (en) * | 2008-03-13 | 2009-09-17 | Dyax Corp | Libraries of genetic packages comprising novel hc cdr3 designs |
EP2132228B1 (en) | 2008-04-11 | 2011-06-22 | Emergent Product Development Seattle, LLC | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
AU2009240481B2 (en) | 2008-04-24 | 2015-07-30 | Takeda Pharmaceutical Company Limited | Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs |
US20110082054A1 (en) * | 2009-09-14 | 2011-04-07 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr3 designs |
DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
CN104583239B (zh) | 2012-05-10 | 2018-09-18 | 生物蛋白有限公司 | 多特异单克隆抗体 |
MY197562A (en) | 2015-09-21 | 2023-06-23 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
CN106119189B (zh) * | 2016-07-11 | 2020-04-10 | 山东亚大药业有限公司 | 胎儿有核红细胞的分离纯化方法及试剂盒 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
US6329507B1 (en) | 1992-08-21 | 2001-12-11 | The Dow Chemical Company | Dimer and multimer forms of single chain polypeptides |
DK0672142T3 (da) * | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
-
1994
- 1994-09-16 AT AT94926336T patent/ATE173740T1/de not_active IP Right Cessation
- 1994-09-16 JP JP7509628A patent/JPH09503759A/ja not_active Ceased
- 1994-09-16 ES ES94926336T patent/ES2126145T3/es not_active Expired - Lifetime
- 1994-09-16 DE DE69414870T patent/DE69414870T2/de not_active Expired - Lifetime
- 1994-09-16 EP EP94926336A patent/EP0720624B1/en not_active Expired - Lifetime
- 1994-09-16 CA CA002169620A patent/CA2169620A1/en not_active Abandoned
- 1994-09-16 AU AU76214/94A patent/AU680685B2/en not_active Ceased
- 1994-09-16 DK DK94926336T patent/DK0720624T3/da active
-
1996
- 1996-03-22 US US08/621,038 patent/US6589527B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK0720624T3 (da) | 1999-08-09 |
CA2169620A1 (en) | 1995-03-30 |
JPH09503759A (ja) | 1997-04-15 |
AU680685B2 (en) | 1997-08-07 |
US6589527B1 (en) | 2003-07-08 |
DE69414870D1 (de) | 1999-01-07 |
DE69414870T2 (de) | 1999-05-12 |
AU7621494A (en) | 1995-04-10 |
EP0720624B1 (en) | 1998-11-25 |
ATE173740T1 (de) | 1998-12-15 |
EP0720624A1 (en) | 1996-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2126145T3 (es) | Redireccionamiento de anticuerpos. | |
DE3852054D1 (de) | Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung. | |
DE3687736D1 (de) | Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung. | |
ATE125362T1 (de) | Monoklonale antikörper gegen glykosyliertes albumin, hybride zellinien, die diese antikörper produzieren, sowie deren verwendung. | |
DE69734109D1 (de) | Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung | |
ATE171207T1 (de) | Monoklonaler antikörper | |
ATE94205T1 (de) | Monoklonale antikoerper gegen melanoma-assoziierte antigene, hybridzellinien, die diese antikoerper produzieren, und ihre verwendung. | |
DK0554344T3 (da) | Farmaceutisk præparat til behandling eller forebyggelse af en malign tumor | |
DE69126607D1 (de) | Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper | |
ES2110993T3 (es) | Anticuerpos monoclonales especificos para la toxina b de clostridium difficile. | |
EP0350690A3 (de) | Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente | |
DE69522689T2 (de) | Zellzyklus-unabhängige, gliomaoberflach-spezifische, menschliche monoklonale antikörper | |
MX9301500A (es) | Anticuerpos construidos con ingenieria genetica | |
Hämmerling et al. | Immunofluorescence analysis of Ig determinants of mouse thymocytes and T cells | |
DE3854999T2 (de) | An karzinoma assoziierte antigene und antikörper, die diese antigene erkennen | |
DE3855280T2 (de) | Von mca 16-88 erkanntes antigen | |
DE3580524D1 (de) | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. | |
ES2059336T3 (es) | Un metodo para preparar anticuerpo monoclonal anti-trichomonas vaginalis. | |
ATE138200T1 (de) | Das von mca-28a32 erkannte antigen | |
ATE207119T1 (de) | Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind | |
ES2093135T3 (es) | Anticuerpos monoclonales contra el complejo plasmina-antiplasmina, procedimiento para su preparacion asi como su utilizacion. | |
Dammann | A. Adler and A. Zempléni," Le baton de l'aveugle. Divination, maladie et pouvoir chez les Moudang du Tchad"(Book Review) | |
RU98104739A (ru) | Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 720624 Country of ref document: ES |